PTEN and neoplasm: To contextualize our data within the framework of currently recognized pathogenic mutations, we examined the number of established pathogenic missense mutations in three well-characterized tumor suppressors, BRCA1, TP53, and PTEN, and compared to those in SMARCB1 (Fig 1h, Extended Data Fig 2b–c).